Muscarinic receptors [1]

在稳态动力学测量中，-天仙碱将 GTP 酶活性的周转数从 0.19 min-1 增加到 2.11 min-1。 R-(+)-hyoscyamine 导致与毒蕈碱乙酰胆碱受体亚型 (m1-m5) 结合的 [3H]NMS 发生置换，pKi 值分别为 8.67、8.51、7.46、8.56 和 8.53。 Hyoscyamine 可防止 CHO 细胞中激动剂诱导的 cAMP 产生刺激，EC50 为 7.8 nM。 S-(-)-hyoscyamine 可将大鼠心脏（心房和心室）膜中毛喉素刺激的环 AMP 合成增强高达 24%。

L-Hyoscyamine（曼陀林；5–20 mg/kg；IV）可延长 MMC 迁移周期的长度[1]。

---

在大鼠体内静脉注射L-莨菪碱（天仙子胺），可显著改变小肠移行性肌电复合波（MMC）的模式。它延长了MMC周期的持续时间，并抑制了MMC III相收缩的传播，这一效应归因于其对毒蕈碱受体的拮抗作用[1]

Animal/Disease Models: Rats[1]
Doses: 5, 10, 20 mg/kg
Route of Administration: IV
Experimental Results: Prolonged the migrating myoelectric complex (MMC) cycle length.

---

Male Wistar rats were fasted for 24 hours before the experiment, with free access to water. L-Hyoscyamine (Daturine) was dissolved in physiological saline and administered intravenously at a specific dose. Myoelectric activity of the small intestine was recorded using implanted electrodes for a continuous period to monitor MMC changes [1]
- Female domestic swine (20-25 kg) were acclimated before the experiment. Atropine (which can be converted to L-Hyoscyamine (Daturine) in vivo) was administered intravenously. Blood samples were collected at predetermined time points (0, 5, 15, 30, 60, 120, 240, 480, 720 minutes) via a jugular vein catheter for the determination of R- and S-hyoscyamine concentrations [2]

Absorption, Distribution and Excretion
Hyoscyamine is completely absorbed via sublingual and oral routes, but precise data on Cmax, Tmax, and AUC are not yet clear. Most hyoscyamine is excreted in the urine as the unmetabolized parent compound. Metabolism/Metabolites Hyoscyamine exists primarily in its unmetabolized form, but a small amount is hydrolyzed to tropine and tropine acid. Rabbit liver homogenates containing (-)-hyoscyamine acylhydrolase can hydrolyze (-)-hyoscyamine to tropine and (-)-tropine acid, but not (+)-hyoscyamine. Biological Half-Life The half-life of hyoscyamine is 3.5 hours. L-hyoscyamine (datulin) (S-hyoscyamine) was detected in plasma as the major enantiomer after intravenous injection of atropine in pigs. Enantioselective LC-ESI MS/MS analysis showed that S-hyoscyamine was rapidly absorbed into the systemic circulation and could be detected within 5 minutes after administration. The lower limit of quantitation of this analytical method was sufficient to track changes in S-hyoscyamine concentration over 12 hours [2].

Hepatotoxicity
Although hyoscyamine has been widely used for decades, it has not been found to be associated with elevated liver enzymes or clinically significant liver damage. Its high safety profile is likely due to its low daily dose and limited duration of use. References on the safety and potential hepatotoxicity of anticholinergic drugs are listed after the "Overview of Anticholinergic Drugs" section. Drug Category: Gastrointestinal Drugs; Anticholinergic Drugs Interactions Levohyoscyamine (0.3 mg/kg) inhibits salivation induced by cholinergic and adrenergic drugs in mice without affecting the associated temperature response. When administered 30 minutes before an adrenergic salivating agent, it does not inhibit salivation induced by D-amphetamine sulfate but still reduces salivation induced by L-isoproterenol tartrate.

[1]. Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats. Eur J Pharmacol. 2003 Apr 25;467(1-3):211-8.

[2]. Application of an enantioselective LC-ESI MS/MS procedure to determine R- and S-hyoscyamine following intravenous atropine administration in swine. Drug Test Anal. Mar-Apr 2012;4(3-4):194-8.

(S)-Atropine is an atropine with a 2S configuration, its function is related to (S)-tropinic acid, and it is the conjugate base of (S)-atropineon. Hyoscyamine is a tropane alkaloid, the levorotatory isomer of atropine, and is usually extracted from plants in the Solanaceae family. The earliest research literature on the effects of hyoscyamine dates back to 1826. Due to its antimuscarinic properties, hyoscyamine is widely used for various treatments. Although hyoscyamine is available in the United States, it has not been approved by the FDA. Hyoscyamine is a natural plant alkaloid derivative and anticholinergic drug used to treat mild to moderate nausea, motion sickness, overactive bladder, and allergic rhinitis. Hyoscyamine has not been shown to cause elevated liver enzymes or clinically significant acute liver injury.
L-Hyoscopolamine has been reported to be present in Scopolia parviflora, Cyphanthera odgersii, and other organisms with relevant data.
Hyoscopolamine is a belladonna alkaloid derivative, a levorotatory form of racemic atropine isolated from Hyoscyamus niger or Atropa belladonna, and possesses anticholinergic activity. As a non-selective competitive antagonist of muscarinic receptors, hyoscyamine inhibits the parasympathetic activity of acetylcholine on salivary glands, bronchial glands, sweat glands, and the eyes, heart, bladder, and gastrointestinal tract. These inhibitory effects lead to reduced secretion of saliva, bronchial mucus, gastric juice, and sweat. Furthermore, its inhibitory effect on smooth muscle can prevent bladder contraction and reduce gastrointestinal motility.
Atropine 3(S)-endoform isomer. See also: Atropine (note moved to); Hyoscyamine (note moved to).

---

Drug Indications
Since hyoscyamine is not approved by the FDA, there are no officially approved indications. Intravenous hyoscyamine has been used to reduce gastric motility, alleviate pancreatic pain and secretions, aid in gastrointestinal imaging, treat anticholinesterase poisoning, treat certain partial atrioventricular block, improve renal visualization, and relieve symptoms of biliary colic and renal colic. Intravenous hyoscyamine is also used preoperatively to reduce oral and respiratory secretions, thus facilitating intubation. Oral hyoscyamine is used to treat functional bowel disorders, relieve symptoms of biliary colic and renal colic, and relieve symptoms of acute rhinitis.

---

Mechanism of Action
Hyoscyamine competitively and nonselectively antagonizes muscarinic receptors in smooth muscle, myocardium, sinoatrial node, atrioventricular node, exocrine node, gastrointestinal tract, and respiratory tract. Antagonism of muscarinic M1, M4, and M5 receptors in the central nervous system can lead to cognitive impairment; antagonism of M2 receptors in the sinoatrial and atrioventricular nodes can lead to increased heart rate and atrial contractility; antagonism of M3 receptors in smooth muscle can lead to decreased intestinal peristalsis, bladder contraction, salivation, gastric juice secretion, bronchial secretion, and sweating, increased bronchiectasis, pupillary dilation, and ciliary muscle paralysis. The main action of antimuscarinic drugs is to competitively antagonize the effects of acetylcholine and other muscarinic agonists. …The receptors affected are peripheral structures stimulated or inhibited by muscarinic substances, namely exocrine glands, smooth muscle, and cardiac muscle. Responses to postganglionic cholinergic nerve stimulation are also inhibited…but not as readily as responses to cholinesterase injection. /Antimuscarinic Drugs/

---

Therapeutic Uses
Adjunctive drugs, anesthetics; antiarrhythmic drugs; antidotes; bronchodilators; muscarinic antagonists; mydriatics; parasympathetic blockers
/L-hyoscyamine is a/racemic mixture…/levorotatory isomer of/levorotatory atropine/, therefore half of atropine is hyoscyamine. Since the dextrorotatory isomer has almost no activity, hyoscyamine is approximately twice as potent as atropine. Its effects and uses are the same as general antimuscarinic drugs, but hyoscyamine is not used in ophthalmology and has minimal effect on inhibiting gastric acid secretion. …Its use is mainly limited to antispasmodics.
Ten male patients with chronic duodenal ulcers underwent enhanced histamine tests before and after treatment with the optimal effective dose of long-acting levorotatory hyoscyamine 0.84 mg (three times daily). During treatment, gastric acid secretion increased, but the amount of secretion decreased significantly, while pepsin and intrinsic factor secretion remained unchanged. In healthy volunteers, levohyoscyamine (0.6 mg, twice daily) significantly affected salivary secretion. Compared to pyrazinamide, levohyoscyamine significantly delayed gastric emptying. Levohyoscyamine inhibited 51% of swallowing-induced esophageal peristalsis. It also affected pupil size and near point distance. For more complete data on the therapeutic uses of (-)-hyoscyamines (a total of 6), please visit the HSDB records page.

---

Pharmacodynamics
Hyoscyamine has not been approved by the FDA and therefore has no official indication. However, it is used as an anticholinergic agent in various treatments. Hyoscyamine has a short duration of action and may require multiple daily doses. Patients should be informed of the risks and symptoms of anticholinergic toxicity.

---

L-hyoscyamine (datulin) is a key mechanism for regulating intestinal MMC as a muscarinic receptor antagonist[1].
Atropine can be converted into L-hyoscyamine (datulin) (S-hyoscyamine) and its enantiomer R-hyoscyamine in pigs. The enantioselective LC-ESI MS/MS method is a reliable tool for quantifying these two enantiomers in plasma[2].

C17H23NO3

289.37

289.167

101-31-5

L-Hyoscyamine sulfate;620-61-1;L-Hyoscyamine-d3

154417

White to off-white solid powder

1.2±0.1 g/cm3

429.8±45.0 °C at 760 mmHg

108.5ºC

213.7±28.7 °C

0.0±1.1 mmHg at 25°C

1.581

1.53

49.77

1

4

5

21

353

3

CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3

RKUNBYITZUJHSG-VFSICIBPSA-N

InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1

[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

配方 1 中的溶解度: ≥ 2.5 mg/mL (8.64 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 2 中的溶解度: ≥ 2.5 mg/mL (8.64 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

---

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (8.64 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液添加到 900 μL 玉米油中并混合均匀。

---

配方 4 中的溶解度: 30% Propylene glycol , 5% Tween 80 , 65% D5W: 5 mg/mL

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。